Understanding the Market | JIUYUAN GENE's stock rose over 7% after earnings, with a mid-term net profit attributable to shareholders of 90.174 million yuan, and sales of orthopedic products increased by over 10% year-on-year

JIUYUAN GENE rose over 7% after earnings, as of the time of writing, up 7.02%, priced at HKD 15.4, with a transaction volume of HKD 10.2428 million. On the news front, on August 19, JIUYUAN GENE released its interim results for the six months ending June 30, 2025, reporting revenue of RMB 639 million, a year-on-year decrease of 9.05%; gross profit of RMB 525 million, a year-on-year decrease of 2.84%; net profit attributable to shareholders of the parent company of RMB 90.174 million, a year-on-year decrease of 14.4%; and earnings per share of RMB 0.37. As of June 30, 2025, the company achieved a total revenue decrease of 9.1% year-on-year, with profit for the period down 14.4% year-on-year. The slight decline in total revenue in the first half of the year was mainly due to a combination of internal and external factors. During this reporting period, the sales volume of the company's orthopedic products increased by over 10% year-on-year, and the hospital penetration rate continued to improve. Focusing on the company's annual operational goals, differentiated business policies are implemented to stabilize the existing market and cultivate incremental markets, striving for steady growth in annual business revenue